[ad_1] Updated Jan. 11, 2024 12:47 pm ET Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug…
Tag: Novartis
WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics
[ad_1] Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up…
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio…
Novartis Raises Mid-Term Sales Growth Targets
[ad_1] Novartis lifted its sales growth guidance for the mid-term after what it called a progress in delivering its pure-play strategy. The Swiss pharmaceutical company upgraded on Tuesday its compound…
Novartis lifts 2023 earnings forecast for third time
[ad_1] Switzerland’s Novartis has today raised its full-year earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for a multiple sclerosis (MS) drug. The Basel-based drugmaker spun…
Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales
[ad_1] Updated Oct. 24, 2023 3:04 am ET Novartis raised its full-year earnings guidance for the third time this year after it reported higher net profit and sales for the…
Novartis unit Sandoz starts trading at 24 Swiss francs after completing spinoff
[ad_1] The Swiss drugmaker announced intentions to spin off the Sandoz business in August, offering stakeholders one Sandoz share for every five Novartis shares via a dividend-in-kind distribution. Novartis said…
Novartis’ Sandoz valued at $11.2 bln in market debut
[ad_1] A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing Rights Oct 4 (Reuters) – Sandoz (SDZ.S)…